Polar Asset Management Partners Inc. Purchases Shares of 27,000 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Polar Asset Management Partners Inc. purchased a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 27,000 shares of the company's stock, valued at approximately $607,000.

Several other large investors have also recently added to or reduced their stakes in NRIX. Amalgamated Bank raised its holdings in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company's stock valued at $49,000 after acquiring an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock valued at $54,000 after acquiring an additional 559 shares in the last quarter. International Assets Investment Management LLC raised its holdings in Nurix Therapeutics by 1,098.4% in the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company's stock valued at $101,000 after acquiring an additional 4,119 shares in the last quarter. Quest Partners LLC raised its holdings in Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company's stock valued at $168,000 after acquiring an additional 1,312 shares in the last quarter. Finally, Bellevue Group AG acquired a new position in shares of Nurix Therapeutics in the 3rd quarter worth approximately $180,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on NRIX shares. Royal Bank of Canada dropped their target price on Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating for the company in a report on Monday, October 14th. HC Wainwright increased their target price on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Oppenheimer increased their target price on Nurix Therapeutics from $27.00 to $30.00 and gave the stock an "outperform" rating in a report on Wednesday, September 4th. Jefferies Financial Group started coverage on Nurix Therapeutics in a report on Friday, October 11th. They issued a "buy" rating and a $41.00 target price for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price target on shares of Nurix Therapeutics in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.75.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 2,368 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total transaction of $57,542.40. Following the sale, the chief financial officer now owns 37,270 shares of the company's stock, valued at approximately $905,661. This trade represents a 5.97 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Gwenn Hansen sold 3,437 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $83,519.10. Following the sale, the insider now directly owns 50,670 shares in the company, valued at $1,231,281. The trade was a 6.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,401 shares of company stock valued at $437,453 over the last three months. Company insiders own 7.20% of the company's stock.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX traded up $1.31 during mid-day trading on Friday, hitting $21.37. The company's stock had a trading volume of 1,021,668 shares, compared to its average volume of 863,137. The company's fifty day simple moving average is $23.75 and its 200-day simple moving average is $21.93. Nurix Therapeutics, Inc. has a one year low of $7.65 and a one year high of $29.56. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -7.34 and a beta of 2.11.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The business had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. On average, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.81 EPS for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.